SCHEMBL4390463

SCHEMBL4390463

N#Cc1ccc(-c2n[nH]cc2CN2CCN(c3cc(C#N)ccn3)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.45
PARP1 P09874 1/20 0.43
TNK2 Q07912 1/20 0.43
TNK1 Q13470 1/20 0.43
HTR7 P34969 1/20 0.40
DRD2 P14416 5/20 0.40
DRD4 P21917 5/20 0.40
DRD3 P35462 5/20 0.40
CHRM4 P08173 1/20 0.40
HRH1 P35367 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
KDM1A O60341 4/20 0.38
AR P10275 1/20 0.38
KCNH2 Q12809 1/20 0.38
LCAT P04180 1/20 0.38
PANK3 Q9H999 1/20 0.37
KDM4E B2RXH2 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ABL1 P00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4244848 0.93 DRD2 (0.46) LRRK2PARP1TNK2TNK1HTR7
SCHEMBL4249833 0.82 GPR39 (0.48) PARP1DRD2DRD4DRD3AR
SCHEMBL4071799 0.80 MAOB (0.50) PARP1DRD4KDM1AARKCNH2
SCHEMBL4248465 0.80 SMO (0.46) PARP1TNK2TNK1DRD2DRD4
SCHEMBL4248453 0.78 KDM4E (0.52) LRRK2PARP1HTR7DRD2DRD4
SCHEMBL4399772 0.78 DRD4 (0.43) DRD2DRD4DRD3HRH1HRH3
SCHEMBL4250993 0.77 MAOB (0.47) PARP1DRD4ARKCNH2KDM4E
SCHEMBL4252187 0.77 KDM4E (0.52) HTR7DRD2DRD4DRD3KDM4E
SCHEMBL4246064 0.76 PPARD (0.42) HTR7DRD2DRD4DRD3CHRM4
SCHEMBL4246264 0.75 DRD2 (0.48) PARP1TNK1DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2009-12-10 US claimed
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IP6K1, IP6K2, IP6K3 LRRK2 659/4885PARP1 2083/4885TNK2 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.